Lixia Diao

This study identifies adaptive stress response (ASR) signatures in inflammatory breast cancer (IBC) that correlate with tumor emboli survival, dissemination, and therapeutic response.

This study identifies YAP1-positive cells in relapsed SCLC that exhibit drug tolerance and transition from SCLC to LCNEC-like features, losing some targets but gaining others.

This study identifies PDK1 and YAP1/TEAD signaling as drivers of acquired resistance to KRAS inhibitors in NSCLC and suggests their co-targeting as a potential therapeutic strategy.

This study uses CyTOF to profile circulating tumor cells in SCLC patients, identifying subtype-specific markers and treatment response correlations.

This study identifies three distinct DDR phenotypes in SCLC associated with chemotherapy response and tumor evolution.

This study examines genomic and TCR repertoire heterogeneity in SCLC, finding that lower TCR heterogeneity and mutational burden correlate with better survival.